8-K: Immunocore Appoints Ranjeev Krishana to Board and Enters New Registration Rights Agreement with Baker Brothers Funds

Immunocore Holdings plc has appointed Ranjeev Krishana to its Board of Directors and entered into a new registration rights agreement with Baker Brothers Funds, granting them certain resale registration rights.

Summary

• Immunocore Holdings plc appointed Ranjeev Krishana to its Board of Directors, effective May 28, 2024.
• Mr. Krishana's appointment was made upon the nomination of Baker Brothers Life Sciences, L.P. and 667, L.P. (collectively, the BBA Funds).
• He will serve as a Class I director until the 2025 annual meeting of shareholders.
• Mr. Krishana is a partner at Baker Bros. Advisors LP and has extensive experience in the pharmaceutical industry.
• In connection with Mr. Krishana's appointment, Immunocore entered into a new registration rights agreement with the BBA Funds.
• This agreement grants the BBA Funds certain resale registration rights for their holdings of Immunocore's ordinary shares, non-voting ordinary shares, and American Depositary Shares.
• The company is obligated to file a resale registration statement within 60 days of a request from the BBA Funds.
• The BBA Funds also have the right to one underwritten offering per calendar year, with a maximum of three total, and no more than two underwritten offerings or block trades in any 12-month period.
• The company will cover certain expenses related to these registrations and indemnify the BBA Funds against certain liabilities.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. The appointment of a new director and the registration rights agreement are standard practices, but the potential for increased selling pressure from the BBA Funds is a slight negative.

Positives

• The appointment of Ranjeev Krishana brings significant pharmaceutical and business development experience to the board.
• The new registration rights agreement provides the BBA Funds with a clear path to potentially monetize their investment in Immunocore.
• The agreement includes a defined timeline for the company to file a resale registration statement, providing certainty to the BBA Funds.

Negatives

• The registration rights agreement could potentially lead to increased selling pressure on Immunocore's stock if the BBA Funds choose to exercise their resale rights.
• The company is obligated to pay certain expenses related to the registrations, which could impact its financials.

Risks

• The BBA Funds could potentially sell a large number of shares, which could negatively impact the stock price.
• The company may face challenges in managing the registration process and associated expenses.
• The underwritten offerings could dilute existing shareholders if the company includes additional securities in the offering.

Future Outlook

The company is obligated to file a resale registration statement within 60 days of a request from the BBA Funds, and the BBA Funds have the right to initiate underwritten offerings, which could lead to future sales of Immunocore shares.

Management Comments

• There are no direct quotes from management in this document.

Industry Context

This announcement is typical for biotech companies that have significant institutional investors. Registration rights agreements are common to allow large investors to liquidate their positions. The appointment of a director from a major investment fund is also a common practice to ensure alignment between the company and its investors.

Comparison to Industry Standards

• The registration rights agreement is a standard practice in the biotech industry, similar to agreements seen with other companies backed by venture capital or private equity firms.
• The terms of the agreement, including the number of underwritten offerings and the company's obligation to file a registration statement, are generally consistent with industry norms.
• The appointment of a director from a major investment fund is also a common practice in the biotech industry, similar to companies such as BeiGene, where Mr. Krishana also serves as a director.

Management Changes

Corporate Governance

Related Party Transactions

• The BBA Funds participated in the company's private offering of convertible notes in February 2024, purchasing a total of $60 million in principal amount.
• The company has a letter agreement with the BBA Funds regarding board representation.

Stakeholder Impact

• Shareholders may experience increased volatility in the stock price if the BBA Funds choose to sell their shares.
• The company will incur expenses related to the registration process, which could impact its financials.
• The appointment of Mr. Krishana could bring valuable expertise to the board.

Next Steps

• Immunocore will need to file a resale registration statement within 60 days of a request from the BBA Funds.
• The BBA Funds may initiate underwritten offerings or block trades to sell their shares.
• The company will need to manage the registration process and associated expenses.

Key Dates

Keywords

registration rights, board of directors, Ranjeev Krishana, Baker Brothers, resale registration, underwritten offering, Immunocore, BBA Funds